Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11408771 | 0.85 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL8624969 | 0.85 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL28723748 | 0.85 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL8624972 | 0.85 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL11410628 | 0.85 | TRPV1 (0.62) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL15364405 | 0.80 | TRPV1 (0.47) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL15246408 | 0.80 | TRPV1 (0.47) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL15246188 | 0.76 | TRPV1 (0.61) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL7539831 | 0.76 | ALOX15 (0.47) | TRPV1ALDH1A1ALOX15 | |
| SCHEMBL20500049 | 0.73 | TRPV1 (0.50) | TRPV1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054886-A1 | Ras antagonists for treating neurodegenerative disorders | RAMOT AT TEL AVIV UNIVERSITY, LTD. (IL) | 2007-03-08 | — | — | US | claimed |
| US-6946485-B2 | Treatment of post-angioplasty restenosis and atherosclerosis with Ras antagonists | RAMOT AT TEL AVIV UNIVERSITY, LTD. (IL) | 2005-09-20 | — | — | US | claimed |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | claimed |
| WO-2004103352-A1 | RAS ANTAGONISTS FOR TREATING NEURODEGENERATIVE DISORDERS | RAMOT AT TEL AVIV UNIVERSITY, LTD. (DE) | 2004-12-02 | — | — | WO | claimed |
| US-20070054886-A1 | Ras antagonists for treating neurodegenerative disorders | RAMOT AT TEL AVIV UNIVERSITY, LTD. (IL) | 2007-03-08 | — | — | US | disclosed |
| US-6946485-B2 | Treatment of post-angioplasty restenosis and atherosclerosis with Ras antagonists | RAMOT AT TEL AVIV UNIVERSITY, LTD. (IL) | 2005-09-20 | — | — | US | disclosed |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| WO-2004103352-A1 | RAS ANTAGONISTS FOR TREATING NEURODEGENERATIVE DISORDERS | RAMOT AT TEL AVIV UNIVERSITY, LTD. (DE) | 2004-12-02 | — | — | WO | disclosed |
| EP-0729354-B1 | FARNESYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV RAMOT (IL) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054886-A1 | Ras antagonists for treating neurodegenerative disorders | HRAS, KRAS, RAC1 | TRPV1 2275/4885ALDH1A1 3911/4885ALOX15 2747/4885 |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RSU1, KSR1, KRAS | TRPV1 2321/4885ALDH1A1 4061/4885ALOX15 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.